Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Kåre I. Birkeland, Marit E. Jørgensen, Bendix Carstensen, et al.
The Lancet Diabetes & Endocrinology (2017) Vol. 5, Iss. 9, pp. 709-717
Closed Access | Times Cited: 332

Showing 1-25 of 332 citing articles:

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
Suetonia C. Palmer, Britta Tendal, Reem A. Mustafa, et al.
BMJ (2021), pp. m4573-m4573
Open Access | Times Cited: 479
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
Mikhail Kosiborod, Carolyn S.P. Lam, Shun Kohsaka, et al.
Journal of the American College of Cardiology (2018) Vol. 71, Iss. 23, pp. 2628-2639
Open Access | Times Cited: 422
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
Yuliya Lytvyn, Petter Bjornstad, Jacob A. Udell, et al.
Circulation (2017) Vol. 136, Iss. 17, pp. 1643-1658
Open Access | Times Cited: 391
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 262-276
Open Access | Times Cited: 376
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association
Joshua J. Joseph, Prakash Deedwania, Tushar Acharya, et al.
Circulation (2022) Vol. 145, Iss. 9
Open Access | Times Cited: 370
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
Sean L. Zheng, Alistair Roddick, Rochan Aghar-Jaffar, et al.
JAMA (2018) Vol. 319, Iss. 15, pp. 1580-1580
Open Access | Times Cited: 349
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
Hiddo J.L. Heerspink, Avraham Karasik, Marcus Thuresson, et al.
The Lancet Diabetes & Endocrinology (2019) Vol. 8, Iss. 1, pp. 27-35
Open Access | Times Cited: 268
Cardiovascular Effects of New Oral Glucose-Lowering Agents
André Scheen
Circulation Research (2018) Vol. 122, Iss. 10, pp. 1439-1459
Open Access | Times Cited: 249
SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Anastasios Tentolouris, Panayotis K. Vlachakis, Evangelia Tzeravini, et al.
International Journal of Environmental Research and Public Health (2019) Vol. 16, Iss. 16, pp. 2965-2965
Open Access | Times Cited: 243
Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
Thomas A. Zelniker, Eugene Braunwald
Journal of the American College of Cardiology (2018) Vol. 72, Iss. 15, pp. 1845-1855
Open Access | Times Cited: 201
Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
Frederik Persson, Thomas Nyström, Marit E. Jørgensen, et al.
Diabetes Obesity and Metabolism (2017) Vol. 20, Iss. 2, pp. 344-351
Open Access | Times Cited: 200
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Beatrice Lupsa, Silvio E. Inzucchi
Diabetologia (2018) Vol. 61, Iss. 10, pp. 2118-2125
Open Access | Times Cited: 167
Dapagliflozin: A Review in Type 2 Diabetes
Sohita Dhillon
Drugs (2019) Vol. 79, Iss. 10, pp. 1135-1146
Open Access | Times Cited: 165
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
Kåre I. Birkeland, Johan Bodegård, Jan W. Eriksson, et al.
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 9, pp. 1607-1618
Open Access | Times Cited: 159
Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy
Miriam Longo, Giuseppe Bellastella, Maria Ida Maiorino, et al.
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 156
<p>Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence</p>
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini
Diabetes Metabolic Syndrome and Obesity (2020) Vol. Volume 13, pp. 161-174
Open Access | Times Cited: 137
Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i—Arrhythmias and Sudden Cardiac Death)
Jia Liao, Ramin Ebrahimi, Zhiyu Ling, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 16
Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population‐based study of older women and men with diabetes
Iliana C. Lega, Susan E. Bronskill, Michael A. Campitelli, et al.
Diabetes Obesity and Metabolism (2019) Vol. 21, Iss. 11, pp. 2394-2404
Closed Access | Times Cited: 133
Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
Narjes Nasiri‐Ansari, Georgios K. Dimitriadis, Georgios Agrogiannis, et al.
Cardiovascular Diabetology (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 129
SGLT-2 Inhibitors and Cardiovascular Risk
Matthew A. Cavender, Anna Norhammar, Kåre I. Birkeland, et al.
Journal of the American College of Cardiology (2018) Vol. 71, Iss. 22, pp. 2497-2506
Open Access | Times Cited: 120
Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti‐diabetic therapies
David S.H. Bell, Edison Gonçalves
Diabetes Obesity and Metabolism (2018) Vol. 21, Iss. 2, pp. 210-217
Closed Access | Times Cited: 114
Carbotoxicity—Noxious Effects of Carbohydrates
Guido Kroemer, Carlos López‐Otín, Frank Madeo, et al.
Cell (2018) Vol. 175, Iss. 3, pp. 605-614
Open Access | Times Cited: 105
Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes
Matthew J. O’Brien, Susan Karam, Amisha Wallia, et al.
JAMA Network Open (2018) Vol. 1, Iss. 8, pp. e186125-e186125
Open Access | Times Cited: 95
Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation
Yumei Ye, Xiaoming Jia, Mandeep Bajaj, et al.
Cardiovascular Drugs and Therapy (2018) Vol. 32, Iss. 6, pp. 553-558
Closed Access | Times Cited: 94
Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study
Björn Pasternak, Peter Ueda, Björn Eliasson, et al.
BMJ (2019), pp. l4772-l4772
Open Access | Times Cited: 87
Page 1 - Next Page

Scroll to top